BIG PICTURE中文

Shorter belts, smaller plates: how GLP-1 drugs are reaching far beyond pharma

By · AI-assisted, human-reviewed and edited · · Updated · 165 sources · Fact-checked · 16 min read (28 min with all details)

How are GLP-1 weight-loss drugs changing things beyond pharma?

About one US adult in eight tells KFF's pollsters they take a GLP-1 drug, and households that start one spend about 5% less on groceries, a Cornell study found, a real change that is still small across whole industries. The sharper story is who gets access, as prices fall and Medicare starts paying while some states and employers pull back, and the stocks have split: Lilly has more than tripled since May 2023 and General Mills has lost more than half its value.

A Manhattan shop, Jim’s Cobbler Concierge, has a word for the trend weight-loss drugs have brought to its belt repairs: “belt-zempic,” Reuters reported in October. In the same report, Stephen Kelly, chief executive of the Texas chain Cobblers Direct, described what some customers do with the extra length on a belt with new holes: “They’ll pull their belt out and show how long their belt originally was. And then they tuck it back into their waistline.”

Dean Coleman and his father alter trousers at Copperfield Tailors, in London’s financial district. “They come in with suitcases of stuff,” said the son, in a Financial Times report carried by The Irish Times.

About one American adult in eight now says they are taking a GLP-1 drug such as Ozempic, Wegovy, Mounjaro or Zepbound, KFF’s polling found. Medicines that began as diabetes treatments are changing what people eat, wear and spend, and they are reaching the country unevenly, depending on who can afford them and whose insurer will pay. Investors tried to price all of this early: in the fall of 2023, Bloomberg described shares of food and drink companies sliding after Walmart’s comments on shoppers using the drugs, and Reuters wrote of investor questions for makers of glucose monitors. Three years on, the record shows a measurable but modest change in spending, a fight over who pays that has only begun, and a list of stock winners and losers whose fortunes, by the companies’ own accounts, often turn on other things.

Half the beans and rice

At Cuba Libre, in Philadelphia’s Old City, a lighter ropa vieja built for customers on the drugs comes with half the usual black beans and rice, WHYY reported in the spring. Guests eating lighter, the owner, Barry Gutin, said, “don’t feel bad that they’re leaving leftovers from a larger portion.”

The same shift shows up in purchase records. Sylvia Hristakeva, an assistant professor at Cornell, and her colleagues followed households’ shopping after someone started one of the drugs and compared them with similar households, the Cornell Chronicle reported. Grocery bills fell about 5% within six months and savory snacks by about a tenth, while yogurt rose a little. When people stopped, their shopping drifted back.

Restaurants feel it as smaller orders rather than empty tables: the market researcher Circana found users visit about as often but order slightly fewer items. Chipotle says it built a high-protein menu with them in mind. Thomas Paulson, head of market insights at the foot-traffic firm Advan Research, has argued that adoption among affluent households “looks to be the larger driver” of Chipotle’s sales slowdown, while calling his data “not a definitive answer.” Chipotle itself has pointed to a pullback among households earning less than $100,000 a year, and it faces surging beef costs, Reuters reported.

Food executives say the overall hit is small. Looking ten years ahead on an earnings call in February, Mondelez’s chief executive, Dirk Van de Put, said “we do not see a significant effect on our overall business,” according to a Motley Fool transcript. Their share prices have suffered anyway, for reasons they mostly place elsewhere, from cocoa at Mondelez and Hershey to weaker consumer sentiment at General Mills and cautious spending at Conagra, Reuters reported.

The numbers behind this

Cornell and Numerator (Hristakeva, Liaukonytė and Feler, Numerator’s chief economist; Numerator supplied the data; Journal of Marketing Research; observational, using matched household purchase records; the Numerator panel of about 150,000 households is the source panel; the main analysis follows 2,602 adopting households, each matched to a similar non-adopter, with transactions from July 2022 to September 2024 and four survey waves, per the authors’ Economics Observatory account and the journal supplement): grocery spending −5.3% within six months, higher-income households −8.2%, savory snacks −10.1%, fast-food chains and coffee shops −8.0%. PwC’s May 2026 refresh of Numerator’s transaction panel, covering about 110,000 households, reported −5.5% for groceries and −8.7% for quick-service restaurants at six to eight months after starting. Mondelez’s estimate is 0.5–1.5% lower volume over ten years, assuming 10–20% US adoption. Smucker’s chief executive, Mark Smucker, said in 2024 that the company had “found no evidence” of an impact (Bloomberg, via Fortune). Circana (January 2026): receipts plus survey data over the first year on the drug, 1% fewer items; its release gives no sample size. WHYY also reports smaller portions at Olive Garden (Darden) and the Cheesecake Factory.

A label on the shelf

The packaged-food response is easiest to see in the store. An AP photograph from January shows “GLP-1 Friendly” meals on a Kroger shelf in Ann Arbor, Michigan, and Conagra had added that label to its Healthy Choice frozen meals, AP reported. Nestlé aimed a whole frozen-meal brand, Vital Pursuit, at people on the drugs, then found most of its sales coming from elsewhere: Jennifer Barnes, its vice president of brand marketing for frozen meals, said 77% of those sales came from households where no one uses them, AP reported.

Grocers are starting to plan for the other end of the prescription. Hy-Vee offered a six-week online course with one-on-one dietitian check-ins, Grocery Dive reported, and its chief executive, Jeremy Gosch, wants to keep those shoppers after the medicine stops. “When they come off of the medication, they’re putting the weight back on,” he said. At the pharmacy counter, the drugs themselves bring in sales but little profit. GLP-1 prescriptions are “a high retail ring, but at an extremely low margin,” Kroger’s then-interim finance chief said on a 2024 earnings call. John Furner, Walmart’s US chief executive, told Bloomberg in 2023 that the company saw a slight pullback among shoppers on the drugs: “Just less units, slightly less calories.”

Clothing is one place the drugs bring in business. At Stitch Fix, chief executive Matt Baer estimated that at least a fifth of new clients are on one, Reuters reported.

The numbers behind this

Conagra: “GLP-1 Friendly” label on 26 Healthy Choice frozen meals in early 2025 (AP). Nestlé: Vital Pursuit launched in the fall of 2024 (AP). Kroger: Todd Foley, then interim CFO, June 2024 (transcript). Walmart: John Furner, October 2023, compared with the total population, unquantified (Bloomberg). Costco: members’ Wegovy cost fell from $1,339 a month in December 2024 to $349 in December 2025 (Costco slides). ThredUp said 43% of one group of buyers, those starting above a size-28 waist, were buying smaller jeans than at sign-up (company figure; no sample or period given; Reuters, October 2026).

Off the plan

Blue Cross Blue Shield of Michigan’s claims for weight-loss drugs had climbed from $8 million in 2021 to $100 million by mid-2024, its chief medical officer, James Grant, said, Bridge Michigan reported. “It’s just unaffordable and we have to make difficult decisions,” he said, as the insurer prepared to phase out coverage for its large-group plans. Letters about the change reached nearly 9,000 people in the state, The New York Times later reported. Andrew Kraftson, a physician whose patients lost coverage, began pointing more of them toward weight-loss surgery, the Times reported, telling them: “No one can take surgery away from you.” Novo, which makes Wegovy, pushed back in a statement to the Times: denying coverage, it said, “reinforces the misconception that obesity is a choice.”

North Carolina’s state employee plan stopped covering the drugs for weight loss in April 2024, while still covering them for diabetes, KFF Health News reported. One state employee said Ozempic had “stopped the food noise in my head,” KFF Health News reported. Her copay had been $25; without coverage, the outlet said, the drug could run up to $1,200 a month. She paid $225 a month instead for a pharmacy-made copy that she believed worked less well.

Access is uneven. A study in JAMA of eligible adults without diabetes found about one in 40 got an obesity prescription, with lower rates in rural areas and in more socially vulnerable places. Yuan Lu, a Yale assistant professor and the study’s senior author, pointed to access to specialists, cost and insurance as possible reasons, the Yale School of Medicine reported. More than half of users told KFF the drugs were hard to afford, including most of those with insurance.

The numbers behind this

JAMA (Kim, Ross, Krumholz, Lu et al., 2025; Epic Cosmos records, July 2020 to October 2024): of 39.1 million eligible adults without diabetes, 2.3% were prescribed semaglutide or tirzepatide for obesity; 1.5% rural vs 2.4% metro; 1.9% in the most socially vulnerable quarter vs 2.6% in the least. These are prescriptions written, not fills. KFF (November 2025, n=1,350): 56% of people who had used a GLP-1 found them hard to afford, including 55% of the insured; 27% of all users were insured yet covered the whole cost out of pocket. Use: KFF 12% current and 18% ever (late 2025, n=1,350; 6% and 12% in spring 2024, n=1,479; 12% current again in KFF’s February–March 2026 poll, n=1,343). Gallup: 11% current for weight loss (n=5,065, late May and early June 2026). All self-reported.

Who picks up the bill

North Carolina’s plan had a bill of its own. In its own statement, it said it estimated that keeping the coverage would have added $48.50 a month per subscriber, doubling premiums for individual members whether or not they took the drugs.

That argument is now moving through state budgets while Washington pushes the other way. California, Pennsylvania, New Hampshire and South Carolina withdrew Medicaid coverage of the drugs for weight loss alone at the start of 2026, some with exceptions, KFF, state and health-plan notices and local reporting show. Massachusetts followed in July, according to a Mass General Brigham Health Plan notice, and Rhode Island in October, according to its health agency. Prices, meanwhile, have tumbled: from about $1,000 or more a month, by Yale’s account, to advertised offers that start at $149 for the lowest-dose Wegovy pill, by Novo’s pricing. Since July, Medicare has covered obesity treatment for eligible patients through a temporary program with a $50 copay, CMS says. It ends at the end of 2027, and we found nothing that settles what comes next. Many employers are staying out: among firms with at least 200 workers that offer health benefits, most of those that don’t cover the drugs for weight loss told KFF they were unlikely to start.

Policy: the dates and the details

Medicare: the GLP-1 Bridge runs from July 2026 to Dec 31, 2027 ($50 copay). The negotiated semaglutide price of $274 for a 30-day supply starts Jan 1, 2027; it is not a patient copay. CMS’s FAQ says BALANCE is not launching in Medicare in 2027 and calls Part D implementation “potential”. Price deals (November 2025): TrumpRx about $350, Medicare $245, also offered to Medicaid.

North Carolina’s state plan: its March 2024 statement projected the drugs’ cost at more than $170 million in 2024 and more than $1 billion over six years, and said the cost “exceeds the amount the State Health Plan spends on cancer, rheumatoid arthritis, and chemotherapy medications.” The treasurer’s projection is reported in KFF Health News, December 2024.

Medicaid (not a full census): California, New Hampshire, Pennsylvania and South Carolina withdrew GLP-1 coverage for weight loss alone on Jan 1, 2026, subject to exceptions; Michigan restricted it to severe cases; Massachusetts ended it in July and Rhode Island on Oct 1, 2026. North Carolina withdrew it and reinstated it in late 2025. Tennessee added it in 2025, with limits. Programs covering obesity fell from 16 to 13 between October 2025 and January 2026, and gross Medicaid GLP-1 spending was almost $9 billion in 2024, up from about $1 billion in 2019 (KFF). CMS took state applications for the voluntary BALANCE price model through July 31, 2026; states may start by Jan 1, 2027, with later entry only at CMS’s discretion.

Employers (KFF 2026 survey, 1,937 firms): 18% of firms with 200+ workers cover the drugs for weight loss, and 33% at 5,000+ (43% in 2025, a change KFF does not call significant). Of those not covering them, 79% say they’re not likely to start, and 12% stopped in the past year.

Compounding: the FDA ended the shortage-era latitude for tirzepatide and semaglutide copies in 2025. In February 2026 it said it intended to act on ingredients in mass-marketed copies and named Hims & Hers. Novo said it sued Hims the same month (allegations, not findings), and in March Hims announced a deal to offer Novo’s approved drugs and limit compounding to clinical need. Editors hold Hims & Hers.

A big claim, and the doubts

One striking claim about life on the drugs comes from Rebecca Diamond, a Harvard economist. Comparing women on the drugs with women who wanted them but hadn’t started, she found that after a year and a half or more those who had not been working were much more likely to have a job, and single women much more likely to have a spouse or live-in partner, she reported in a working paper that has not been peer-reviewed. She thinks first impressions are part of the reason.

It is one working paper, and others find less. Robert Kaestner and Cuiping Schiman, also economists, saw little sign of changes in employment, marriage or mental health among adults with diabetes, a different group, the University of Chicago’s Harris School reported. Stigma runs the other way as well: in one experiment published in the International Journal of Obesity, US adults judged fictional women more harshly if they lost weight on a GLP-1 than through diet and exercise. In Harvard’s account of the paper, Diamond raises the harder possibility: maybe “it’s extra stigmatizing to be an overweight person if you can’t afford these drugs.”

The numbers behind this

Diamond (NBER working paper 35387, June 2026, not peer-reviewed; Understanding America Study, with GLP-1 use recorded from December 2024 to February 2025 and outcomes through spring 2026; 242 women who started a GLP-1 for weight loss, against 850 matched women who wanted to; main estimates cover women only, as male starters were too few; the paper doesn’t give the number of women in each subgroup): at six or more quarters after starting, employment rose 26.9 percentage points among women not employed at the start (standard error 8.4; 13.2 over all quarters), and being married or living with a partner rose 28.6 points among women single at the start (standard error 7.1; 18.3 over all quarters). Partnered women showed no change in partnership, and employment among women already working fell 4.4 points. She says better work capacity may explain part of the employment gain, and she calls Kaestner and Schiman’s paper complementary. Goldman Sachs economists Joseph Briggs and Devesh Kodnani estimated in 2024 that the drugs could lift the US GDP level by 0.4% in a baseline scenario; that’s a scenario, not an annual growth rate. Stigma: Post and Persky, International Journal of Obesity, 2024; 357 US adults.

What the market guessed

ResMed, which sells machines for sleep apnoea, lost about a quarter of its value in the autumn of 2023, when Reuters described its machines as “expected to face a hit from GLP-1 drugs.” Its revenue has since grown about a third, and an analysis of insurance claims by the data firm IQVIA, which the company presented, found patients with a GLP-1 prescription were more likely to start the therapy, not less. Its chief executive, Mick Farrell, called the drugs “a clear tailwind” on a 2024 earnings call. Its rival Philips, meanwhile, agreed to halt US sales of new sleep-apnoea machines pending corrective action after a recall, AP reported in January 2024. Intuitive Surgical, which makes surgical robots, told a similar story in its annual report: US weight-loss procedures on its robots “declined modestly” in 2024 while its total procedures grew strongly.

Elsewhere other problems loomed larger. Writing after Dexcom’s sales disruption in 2024, Keith Speights, a Motley Fool analyst, said its troubles “don’t appear to be related” to the drugs; an FDA warning letter followed in 2025, Reuters reported. Hershey’s chief executive, Michele Buck, described “a mild year-on-year impact” from GLP-1s on a 2024 call, according to an Equibles transcript; cocoa nearly tripled that year, Reuters reported. Walmart’s own results over the same years show e-commerce and advertising growth.

The two leading drugmakers have also diverged. Novo Nordisk’s shares have roughly halved as it lost ground to Lilly and to copies and cut prices and guidance; its chief executive, Mike Doustdar, described “a year of unprecedented pricing pressure,” Reuters reported. Lilly’s have more than tripled. Of the 24 stocks below with a documented GLP-1 link, 11 rose, 13 fell, and only five beat a fund that tracks the S&P 500, the broad US market index. The table says what each company or analyst said about the drugs and what else was going on; it doesn’t measure how much of each move the drugs explain.

What $100 put into each stock at the end of May 2023 was worth on Nov 2, 2026 ($), stocks with a documented GLP-1 link

Food and drink makers are most of the stocks below $100, 8 of the 13, and all 8 charted fell. Diabetes-device makers fell too, and executives at these companies mostly cite other causes. Lilly and the big retailers rose.

DrugmakersFood and drinkRetail and restaurantsMedical devicesFitness, telehealth, airlines and the S&P 500

Eli LillyEli Lilly: $329 (Drugmakers)$329Hims & Hers*Hims & Hers*: $282 (Fitness, telehealth, airlines and the S&P 500)$282WalmartWalmart: $261 (Retail and restaurants)$261United AirlinesUnited Airlines: $230 (Fitness, telehealth, airlines and the S&P 500)$230CostcoCostco: $203 (Retail and restaurants)$203S&P 500 fund (SPY)S&P 500 fund (SPY): $180 (Fitness, telehealth, airlines and the S&P 500)$180KrogerKroger: $151 (Retail and restaurants)$151Intuitive SurgicalIntuitive Surgical: $142 (Medical devices)$142Viking Therapeutics*Viking Therapeutics*: $122 (Drugmakers)$122MedtronicMedtronic: $120 (Medical devices)$120ResMedResMed: $111 (Medical devices)$111AbbottAbbott: $108 (Medical devices)$108MondelezMondelez: $90 (Food and drink)$90SmuckerSmucker: $90 (Food and drink)$90Planet FitnessPlanet Fitness: $87 (Fitness, telehealth, airlines and the S&P 500)$87ChipotleChipotle: $79 (Retail and restaurants)$79PepsiCoPepsiCo: $77 (Food and drink)$77DexcomDexcom: $72 (Medical devices)$72HersheyHershey: $66 (Food and drink)$66DiageoDiageo: $58 (Food and drink)$58Constellation BrandsConstellation Brands: $58 (Food and drink)$58InsuletInsulet: $56 (Medical devices)$56Novo Nordisk (ADR)Novo Nordisk (ADR): $50 (Drugmakers)$50ConagraConagra: $42 (Food and drink)$42General MillsGeneral Mills: $41 (Food and drink)$41Eli LillyEli Lilly: $329 (Drugmakers)$329Hims & Hers*Hims & Hers*: $282 (Fitness, telehealth, airlines and the S&P 500)$282WalmartWalmart: $261 (Retail and restaurants)$261United AirlinesUnited Airlines: $230 (Fitness, telehealth, airlines and the S&P 500)$230CostcoCostco: $203 (Retail and restaurants)$203S&P 500 fund (SPY)S&P 500 fund (SPY): $180 (Fitness, telehealth, airlines and the S&P 500)$180KrogerKroger: $151 (Retail and restaurants)$151Intuitive SurgicalIntuitive Surgical: $142 (Medical devices)$142Viking Therapeutics*Viking Therapeutics*: $122 (Drugmakers)$122MedtronicMedtronic: $120 (Medical devices)$120ResMedResMed: $111 (Medical devices)$111AbbottAbbott: $108 (Medical devices)$108MondelezMondelez: $90 (Food and drink)$90SmuckerSmucker: $90 (Food and drink)$90Planet FitnessPlanet Fitness: $87 (Fitness, telehealth, airlines and the S&P 500)$87ChipotleChipotle: $79 (Retail and restaurants)$79PepsiCoPepsiCo: $77 (Food and drink)$77DexcomDexcom: $72 (Medical devices)$72HersheyHershey: $66 (Food and drink)$66DiageoDiageo: $58 (Food and drink)$58Constellation BrandsConstellation Brands: $58 (Food and drink)$58InsuletInsulet: $56 (Medical devices)$56Novo Nordisk (ADR)Novo Nordisk (ADR): $50 (Drugmakers)$50ConagraConagra: $42 (Food and drink)$42General MillsGeneral Mills: $41 (Food and drink)$41

Price returns, excluding dividends: $100 in the S&P 500 fund became $180. *Editors hold Hims & Hers and Viking Therapeutics.

Our calculation from Nasdaq official closes, May 31, 2023 to Nov 2, 2026 (S&P 500 via the SPY fund).
Show the data table
Stock Since May 31, 2023 (%) Value of $100 ($) GLP-1 link, in the company’s or analysts’ words Other big drivers documented
Eli Lilly 228.5 329 Its weight-loss drugs drove the 2025 rally, Reuters reported GLP-1 sales; cancer drugs add growth
Hims & Hers* 182.3 282 Its weight-loss specialty, including compounded GLP-1s, is “an accelerant” (CFO Yemi Okupe, 2024 call) Revenue excluding its GLP-1 offering grew 43% in 2024
Walmart 160.8 261 “Just less units, slightly less calories” (US CEO John Furner, Bloomberg, 2023) E-commerce and advertising growth
United Airlines 130.1 230 Modelled fuel savings only (Jefferies) Premium, business and loyalty revenue
Costco 103.4 203 GLP-1 price cuts hit it, but it “found ways to both offset those impacts” and lift prescriptions (CFO Gary Millerchip, 2026 call, via Stock Analysis) Membership growth and fee increases
S&P 500 fund (SPY) 80.0 180 — —
Kroger 50.8 151 Pharmacy growth from “core pharmacy scripts and growth in GLP-1s” (CFO David Kennerley, 2025 call) E-commerce growth, buybacks
Intuitive Surgical 41.9 142 US weight-loss procedures on its robots “declined modestly” (10-K) Procedure growth and its new robot
Viking Therapeutics* 22.2 122 Its obesity drug’s trial results sent shares up more than 40% before the open (Reuters) GLP-1 trial results; a liver-disease drug
Medtronic 20.0 120 No “meaningful change” to its diabetes outlook (CEO Geoff Martha, 2023, MedTech Dive) New heart products, insulin pumps
ResMed 10.5 111 Called “a clear tailwind” (CEO Mick Farrell, 2024 call) Sleep-apnoea device demand and margins; rival Philips agreed to suspend new US machine sales pending corrective action after a recall (AP)
Abbott 8.0 108 Projected GLP-1 users as “a real small fraction” of its markets (CEO Robert Ford, 2023 call, via Stock Analysis) Glucose-monitor growth; a baby-formula verdict
Mondelez −9.6 90 Up to 1.5% lower volume over ten years (CEO Dirk Van de Put’s scenario, 2026 call) Cocoa costs and price increases
Smucker −10.4 90 Has “found no evidence” of an impact (CEO Mark Smucker, Bloomberg, 2024) The Hostess deal, coffee costs, tariffs
Planet Fitness −13.0 87 A potential accelerator, in Investing.com’s summary of KeyBanc, which rates it Overweight A chief executive change and slower franchise growth (Reuters)
Chipotle −20.8 79 GLP-1 adoption “looks to be the larger driver” of weak sales (Advan Research, a foot-traffic data firm) Weaker spending and beef costs, Reuters reported
PepsiCo −23.0 77 CEO Ramon Laguarta saw no “direct impact” in early 2025 (Food Dive); this year, “more opportunities than threats, but there are both” Price fatigue, weak volumes, tariffs
Dexcom −27.7 72 Its troubles “don’t appear to be related” (Keith Speights, Motley Fool analyst) Sales-force problems, guidance cuts, an FDA warning
Hershey −34.1 66 Seeing “a mild year-on-year impact” (CEO Michele Buck, 2024 call, via Equibles) Cocoa prices nearly tripled in 2024
Diageo −41.9 58 Fundsmith founder Terry Smith sold partly on GLP-1 worries; Diageo didn’t immediately respond to MT Newswires Latin American stockpiles and a drinking slowdown
Constellation Brands −42.1 58 Sees “negligible to no impact” on its business (CEO Bill Newlands, 2025, via Investing.com) Hispanic customers spending less, tariffs
Insulet −44.0 56 Possible slower progression to insulin (CEO Jim Hollingshead, 2023 conference, via Stock Analysis) Weak retention among type 2 users, guidance cuts
Novo Nordisk (ADR) −49.6 50 “a year of unprecedented pricing pressure” (CEO Mike Doustdar, Reuters, 2026) Losing share to Lilly and copies; price cuts
Conagra −57.6 42 Suitable products are “an opportunity” (CEO Sean Connolly, Food Dive) Higher costs, cautious spending, a dividend cut (Reuters)
General Mills −58.7 41 Called “a lasting influence” (CEO Jeff Harmening, 2026 conference, via Investing.com) Weaker consumer sentiment, forecast cuts (Reuters)

Sources: our calculation from Nasdaq closes; company releases, filings and call transcripts; Reuters, Bloomberg, Food Dive, MT Newswires, Advan Research, Investing.com and the Motley Fool as named, all listed below.

How we measured the stock moves

Price returns, excluding dividends, from the May 31, 2023 close to the Nov 2, 2026 close, our calculation from Nasdaq official closes; the S&P 500 is measured through the SPY fund (+80.0%). We start at the end of May 2023, before the selloff that followed early heart-trial results for Wegovy in August. Between Aug 7 and Oct 31, 2023, ResMed fell 24%, Insulet 49%, Dexcom 27% and Intuitive Surgical 15%, while SPY fell 7%. Across the 24 selected stocks, the median price return was −10% and the average +22%; Lilly gained the most, 229%, and General Mills fell the most, 59%. ResMed’s filings show revenue rising from $4,223 million in fiscal 2023 to $5,653 million in fiscal 2026, about 34%. Its IQVIA claims analysis is observational, covered July 2021 to September 2025 and included 1,954,000 patients with GLP-1 initiation; a prescription claim did not establish continued use. It is one selected period and a selected group of stocks, so it says nothing about long-run averages, and past moves are not a forecast. WeightWatchers is left out because its bankruptcy makes the price record unreliable. BellRing Brands and Simply Good Foods fell about 74% and 66% even though users spend more on protein shakes (Numerator); we found no company statement tying those falls to GLP-1s, so they aren’t in the table.

The next few years, in simple math

We don’t predict share prices or forecast usage, but the arithmetic is simple enough to do in the open. If the share of adults using these drugs keeps rising at its pace since spring 2024, about one in four would be on one by mid-2030, or about 70 million people. If growth slows enough to reach only the 55 million users by 2035 that Morgan Stanley estimates, as reported by Baking Business, it would be about one in six. Surveys and bank estimates measure different things, so those two paths aren’t like-for-like. Apply Cornell’s measured cuts to those households, and US grocery spending would sit about 1.5% to 2.4% below where it would otherwise be, or roughly $13 billion to $21 billion a year. This is our arithmetic, not a forecast.

Even the high case is under half of what US grocery spending rose in 2025 alone, which helps explain both why companies can call the effect small and why it’s hard to find in their results. It could still matter for the most exposed products: salty snacks would be about 4.5% lower in the high case, and fast-food and coffee chains about 3.6%.

Our arithmetic, not a forecast: the workings

Inputs: 269.8 million US adults (our subtraction from Census’s July 2025 estimates); about 134 million households (Census, 2025 American Community Survey); current use 6% in spring 2024 and 12% in early 2026 (KFF): only two poll endpoints, showing a six-point rise over about 22 months, or 3.3 points a year; the high case extends that rate from March 2026 to mid-2030. 21% of households included a current user in May 2026 (Numerator via PwC); separately, Circana’s “Chain Reactions” article reported annual household incidence of 23% in fall 2025, which isn’t a current-use estimate. Measured cuts per household with a user: groceries −5.3%, savory snacks −10.1%, limited-service restaurants −8.0% (Cornell). Totals: groceries about $896 billion (BLS spending per unit × units, our multiplication), salty snacks $42.5 billion (Circana), limited-service restaurants $516 billion (USDA). Effect = household share × measured cut × total, held at 2025 population and prices. This assumes affected households account for the same share of spending as their share of households. For the low case, we draw a straight line from 12% in March 2026 to 55 million users at the end of 2035, holding the adult population fixed, and read it at mid-2030: 15.7%, or 42 million adults. For future household shares we average two conversions (adult-use share × 21/12, and 1 − (1 − adult-use share)^(269.8/134)), then round. Our BLS calculation is $6,491 × 137.994 million consumer units = $895.7 billion in 2025, against $6,224 × 135.760 million = $845.0 billion in 2024, a rise of $50.7 billion. Category coverage differs, particularly savory versus salty snacks, so these are illustrations.

Case Adults using Households Groceries Salty snacks Limited-service restaurants
Today 12%, 32M 21% −1.1%, ~$10B −2.1%, ~$0.9B −1.7%, ~$9B
Low, mid-2030 16%, 42M 28% −1.5%, ~$13B −2.8%, ~$1.2B −2.2%, ~$12B
High, mid-2030 26%, 70M 45% −2.4%, ~$21B −4.5%, ~$1.9B −3.6%, ~$19B

These are yearly levels below a world without the drugs, not predicted falls in sales; population and prices can move sales the other way. Groceries rose about $51 billion in 2025.

What could make these too high: the effects faded after six months, many people stop, and lower-income newcomers may cut less. Too low: stronger drugs, or the higher-income cut of −8.2%, which gives about −3.7% in the high case. KFF’s last two readings were flat at 12%, so “no change” is also a real case. Surveys and bank estimates measure different things: our 32 million is self-reported in surveys, while Morgan Stanley’s figures start from a far lower count of treated patients, and we haven’t read its underlying note. Don’t compare them like-for-like.

How the named forecasts compare: Morgan Stanley, as reported by Baking Business (April 2026), about 55 million US users by 2035, with US calories 1.6% lower. Circana (November 2025), GLP-1 households buying 35% of food and drink units by 2030, a share of purchases rather than a fall. Mondelez, 0.5–1.5% lower volume over ten years at 10–20% adoption. Goldman Sachs (May 2025; Asad Haider, head of its healthcare research business unit), a $95 billion global obesity-drug market by 2030, cut from $130 billion on lower prices. IQVIA (April 2026), $92 billion of obesity-medicine sales in 2026 at list prices. The last two measure drug revenue, so they aren’t comparable.

A crowded field

A two-company market is filling up. Lilly and Novo now sell pills as well as injections, and behind them come longer-acting shots and new approaches: Amgen’s monthly MariTide, a drug Pfizer gained by buying Metsera, Roche’s programs and Structure Therapeutics’ pill are all in trials, the companies say. Even the leaders can stumble: Novo’s CagriSema missed its goal in a head-to-head trial against tirzepatide, the drug in Lilly’s Zepbound, Novo reported. Lilly says it plans to submit retatrutide, a weekly triple-action shot, to the FDA early next year.

Viking Therapeutics, one of the smaller challengers, has finished enrolling about 5,500 patients in two late-stage trials of its injection and expects them to finish in 2027, and late-stage trials of its pill began in October, the company says. Editors hold Viking, and we make no call on its odds. Competition is also arriving from patent expiries. The main patent on semaglutide, the drug in Ozempic and Wegovy, runs into the next decade in the US, Europe and Japan, Novo’s annual report says, but India, Canada and Brazil are already opening to generics. Goldman Sachs, for its part, cut its market forecast last year on expectations of falling prices.

The pipeline and the patents

These figures come from different trials, with different patients and lengths, and most are company-reported, so they shouldn’t be ranked.

Drug (company) Type Latest reported weight loss Stage
Foundayo, orforglipron (Lilly) Daily pill ATTAIN-1, 3,127 people: 12.4% vs 0.9% at 72 weeks, assuming continued treatment FDA approved April 2026
Oral Wegovy (Novo) Daily pill OASIS 4, 307 people: 16.6% at 64 weeks if taken as directed FDA approved December 2025
Retatrutide (Lilly) Weekly shot TRIUMPH-4, 445 people with obesity and knee arthritis: 28.7% vs 2.1% at 68 weeks, assuming continued treatment Phase 3; US filing planned early 2027
CagriSema (Novo) Weekly combination REDEFINE 4, 809 people: 23.0% vs tirzepatide’s 25.5% at 84 weeks, assuming adherence Filed December 2025
MariTide (Amgen) Monthly or less frequent shot Phase 2, 465 people without diabetes: 16.3–19.9% vs 2.6% at 52 weeks, assuming adherence Phase 3
PF-08653944, from Metsera (Pfizer) Monthly-capable shot VESPER-3, about 54 people per arm: up to 12.3% above placebo at 28 weeks, assuming adherence Phase 3 under way
Enicepatide, CT-388 (Roche) Weekly shot CT388-103, 469 people: 22.5% above placebo at 48 weeks, efficacy analysis Phase 3 under way
Aleniglipron (Structure) Daily pill Company reported further weight loss in an open-label extension; we couldn’t confirm its sample Phase 3 began August 2026
VK2735 shot (Viking) Weekly Phase 2 VENTURE, 176 people: up to 14.7% vs 1.7% at 13 weeks Phase 3 fully enrolled; 78 weeks; finishing 2027
VK2735 pill (Viking) Daily Phase 2 VENTURE-Oral, about 280 planned: up to 12.2% vs 1.3% at 13 weeks Phase 3 began October 2026; 68 weeks

Patents and generics (expiry, approval and launch are separate events): US semaglutide compound patent 2032, and other patents may matter; Japan and Germany 2031, and patent status varies across Europe; China 2026, which doesn’t by itself show generics approved (Novo annual report). Dr. Reddy’s launched in India in March 2026. Brazil’s patent expired in March 2026, and Anvisa registered EMS’s synthetic semaglutide, Ozivy, for type 2 diabetes in May; patent expiry alone doesn’t authorise a sale. Canada approved its first generic in April 2026 and its first for weight loss in June (Health Canada). In the US, the older drug liraglutide already has generics.

The trial that said no

The drugs keep being tried on other diseases because obesity sits underneath so many of them, and because the hormone they mimic acts on more than appetite. Some of those bets have paid off in trials. In SELECT, published in the New England Journal of Medicine, a trial of more than 17,000 people with heart disease and without diabetes, semaglutide cut the risk of major heart events by a fifth in relative terms. The FDA has since approved these drugs for heart risk, sleep apnoea, kidney disease in people with diabetes, and a form of liver disease.

A good theory isn’t always enough. Novo’s two large trials of oral semaglutide in Alzheimer’s disease did not slow its progression, the company reported, and a late-stage trial of an older GLP-1, exenatide, did not slow Parkinson’s, despite earlier promise, The Lancet published. Excess body fat is linked to a long list of cancers, the International Agency for Research on Cancer found, but that doesn’t show these drugs prevent them.

The evidence, disease by disease

FDA-approved uses: type 2 diabetes (the class’s original use; Mounjaro May 2022); weight management (Wegovy June 2021); heart risk with established heart disease (Wegovy March 2024; SELECT, 17,604 people, 6.5% vs 8.0% major events over a mean follow-up of 39.8 months); sleep apnoea with obesity (Zepbound December 2024); kidney disease with type 2 diabetes (Ozempic January 2025; FLOW, 3,533 people, per the FDA label); MASH liver disease (Wegovy August 2025, accelerated approval).

Positive trials without a separate approval we could verify: knee arthritis (STEP 9, 407 people); heart failure (STEP-HFpEF, 529 people treated for 52 weeks; SUMMIT, 731 people followed for a median 104 weeks, 9.9% vs 15.3% for cardiovascular death or worsening heart failure, driven by worsening failure); alcohol (two small trials: 48 people over nine weeks and 108 people over 26 weeks).

Failed or unproven: Alzheimer’s (EVOKE and EVOKE+, Novo, 2025); the International Agency for Research on Cancer’s review links excess body fat to 13 cancers but doesn’t test these drugs; Parkinson’s (exenatide, The Lancet, 2025); cancer prevention, drug addiction and dementia prevention rest on associations and rationale only. An observational study using VA records for about 2 million veterans treated for diabetes during October 2017–December 2023 examined 175 outcomes and linked GLP-1 use to lower risk of some outcomes and higher risk of others (Xie, Choi and Al-Aly, Nature Medicine, 2025).

Weight loss in main trials, in adults without diabetes: semaglutide 2.4 mg 14.9% vs 2.4% on placebo over 68 weeks (STEP-1, 1,961 people); tirzepatide 15.0–20.9% across doses vs 3.1% on placebo over 72 weeks (SURMOUNT-1, 2,539 people). These are averages, not what every user loses. Safety, from the FDA labels: stomach-related side effects are common; labels warn of gallbladder disease, pancreatitis and kidney injury from dehydration; Zepbound’s boxed warning concerns thyroid tumors seen in rats, with human relevance unknown; in November 2026 the FDA required all GLP-1 labels, tirzepatide’s included, to warn of a potential increased risk of a rare eye condition, NAION, which Europe’s regulator already lists as a very rare side effect of semaglutide.

Who keeps taking them

Many people don’t stay on the drugs: in a study of about 125,000 users in JAMA Network Open, about two-thirds of those without diabetes had stopped within a year, and in two trials published in JAMA, patients switched to placebo regained part of what they had lost within about a year. Cornell’s shoppers drifted back toward their old carts too. Who keeps taking them, we think, depends partly on who is paying.

The numbers behind this

Rodriguez et al., JAMA Network Open, 2025 (125,474 users who started in 2018–2023): 64.8% of those without type 2 diabetes stopped within a year, and 46.5% with it. STEP-4 (803 randomized; 268 switched to placebo): about 7% regained, as a share of weight at the switch, over 48 weeks. SURMOUNT-4 (670 randomized; 335 switched): 14% over 52 weeks.

Three news stories were read through the copies we list, because we couldn’t open the originals: Reuters on the cobblers, The New York Times on Michigan and the Financial Times on London.

What to watch next

January 2027
Medicare's negotiated semaglutide price of $274 for a 30-day supply takes effect, and states in the voluntary BALANCE Medicaid price model reach its last scheduled start date.
2027
Viking expects its late-stage injection trials to finish, and Lilly plans to file retatrutide with the FDA.
End of 2027
Medicare's temporary GLP-1 Bridge ends. Nothing we read establishes permanent obesity coverage after that.

Quick questions

What are GLP-1 drugs?

Medicines such as Ozempic and Wegovy (semaglutide, Novo Nordisk) and Mounjaro and Zepbound (tirzepatide, Eli Lilly) that mimic gut hormones, slowing digestion and reducing appetite. Approved for type 2 diabetes and obesity, they produced average weight loss of about 15–21% in their main trials in adults without diabetes.

Have GLP-1 drugs hurt food companies?

Households that start them buy less, especially snacks: about 5% less grocery spending in the first six months, a Cornell study found. Most food makers say the overall effect on their sales is small so far; they also cite cautious consumers and high costs.

Will GLP-1 use keep growing?

We don't forecast it. If the rise in use since 2024 simply continued, about one adult in four would be using one by mid-2030; if it slowed to reach the 55 million users by 2035 that Morgan Stanley estimates, as reported by Baking Business, about one in six. That's our arithmetic, not a forecast, and KFF's last two readings were flat at 12%.

Updates

  • : Updated Nov 9, 2026: The FDA required makers of all GLP-1 drugs, including Novo Nordisk's Ozempic and Wegovy and Eli Lilly's Mounjaro, Zepbound and Foundayo, to add to their labels' Warnings and Precautions a "potential increased risk" of NAION, a rare optic-nerve condition that can cause sudden vision loss in one eye, "including permanent vision loss," NBC News reported. In the FDA's analysis of 126 trials, the rate was 6.4 events per 100,000 patient-years on the drugs vs 3.8 on placebo or other diabetes medicines; the agency found no mechanism. It tells doctors to consider stopping the drug if NAION develops, "unless the benefits of treatment clearly outweigh the risk." Both companies said patient safety is their top priority (NBC News).
Sources: Our calculation: Nasdaq official closes, May 31, 2023 to Nov 2, 2026 · Cornell Chronicle: Hristakeva, Liaukonytė and Feler, household purchases after GLP-1 adoption (Journal of Marketing Research) · Reuters, Danielle Kaye, Arriana Mclymore and Alexander Marrow, Oct 2026: cobblers and tailors (read via WSAU; Reuters original not opened) ·
+ 162 more

Accessed Nov 3, 2026: KFF Health Tracking Poll: GLP-1 use (n=1,350, Oct–Nov 2025) · CMS: Medicare GLP-1 Bridge · Food Dive: food makers on GLP-1s (PepsiCo, Conagra executives) · Constellation Brands at the Barclays conference (transcript, via Investing.com) · ResMed: fiscal Q2 2026 earnings presentation (IQVIA claims analysis) · Advan Research: Chipotle's sales and GLP-1 adoption (Thomas Paulson, Head of Market Insights) · Motley Fool: Dexcom's fall (Keith Speights) · Goldman Sachs Research: obesity-drug market cut to $95B by 2030 (Asad Haider) · JAMA Network Open: discontinuation of GLP-1 drugs (Rodriguez et al., n=125,474) · Baking Business: Morgan Stanley sees GLP-1 use rising faster than projected · Circana: GLP-1 households projected to buy 35% of US food and beverage units by 2030 · KFF: 2025 Employer Health Benefits Survey · Hims & Hers: Q4 and full-year 2024 results · KFF: 2026 Employer Health Benefits Survey · NEJM: SELECT trial, Lincoff et al. (PubMed record) · Investing.com: KeyBanc on Planet Fitness and GLP-1s · IQVIA: the outlook for obesity medicines, 2026 to 2030 · Circana: GLP-1 users aren't ditching restaurants · Walmart: Q2 FY2025 results (e-commerce and advertising growth) · Reuters (via Investing.com): Lilly joins the trillion-dollar club on weight-loss demand · AP: Philips stops US sales of sleep apnea machines after recall · WHYY: restaurants add smaller portions for GLP-1 users (Alan Yu) · The New York Times, Dani Blum, Dec 2024: lost coverage in Michigan (read via InsuranceNewsNet, from West Hawaii Today; NYT original not opened) · KFF Health News: North Carolina and obesity-drug coverage (Melba Newsome) · AP: food companies target GLP-1 users with labels (Dee-Ann Durbin) · Grocery Dive: grocers and shoppers coming off the drugs (Peyton Bigora) · JAMA: obesity prescribing among eligible adults (Kim, Ross, Krumholz, Lu et al.) · Harvard: Rebecca Diamond's working paper on women, jobs and partnership · Chicago Harris: Kaestner and Schiman on adults with diabetes · KFF: Medicaid coverage of and spending on GLP-1s (Elizabeth Williams) · CMS: negotiated prices for 2027 · Novo Nordisk: 2025 annual report (patent expiries) · Health Canada: first generic semaglutide for weight loss · Viking Therapeutics: Q3 2026 results and corporate update · Novo Nordisk: EVOKE trials in Alzheimer's disease · The Lancet: exenatide in Parkinson's disease, Vijiaratnam et al. (University of Plymouth copy) · BLS: Consumer Expenditures 2025 (grocery base for our arithmetic) · Census Bureau: Vintage 2025 population estimates (adults) · PwC: GLP-1 consumer trends (Numerator panel refresh, May 2026) · Financial Times, Dec 2025: weight-loss jabs in the City of London (read via The Irish Times) · Mondelez: Q4 2025 earnings call (Motley Fool transcript, via Finviz) · Reuters (via MarketScreener): Chipotle and Mondelez shares slide, Feb 2026 · Chipotle: high-protein menu release · Yale School of Medicine: Yuan Lu on who gets the drugs · Bloomberg (via Bloomberg Law): Walmart's John Furner on GLP-1 shoppers, Oct 2023 · Bloomberg (via Fortune), Deena Shanker: Mark Smucker on GLP-1s, Oct 2024 · Kroger: Q1 2024 earnings call transcript (Todd Foley) · Kroger: Q2 2025 earnings call transcript · Costco: Q4 FY2026 earnings call (via Stock Analysis) · Costco: 2026 annual meeting slides (Wegovy cost) · Hershey: Q3 2024 earnings call (via Equibles) · Reuters (via Investing.com): Hershey and cocoa, Feb 2025 · ResMed: Q4 FY2024 earnings call transcript · Reuters (via MarketScreener): Novo's 2026 guidance, Feb 2026 · Abbott: Q3 2023 earnings call (via Stock Analysis) · Intuitive Surgical: 2024 Form 10-K · Hims & Hers: Q2 2024 earnings call transcript · Medtronic: Q2 FY2024 commentary and call (via MedTech Dive) · General Mills at CAGNY 2026 (transcript, via Investing.com) · PepsiCo: Q4 2025 earnings call transcript · Insulet: Baird conference, Sep 2023 (via Stock Analysis) · MT Newswires (via Tiger Brokers): Terry Smith on Diageo, Jan 2025 · Jefferies: Weigh to Go (airline fuel estimate), Oct 2023 · Reuters (via Investing.com): Dexcom's FDA warning letter, Mar 2025 · Goldman Sachs Research: Briggs and Kodnani on obesity drugs and GDP, 2024 · International Journal of Obesity: Post and Persky on stigma, 2024 (open copy on PMC) · Nature Medicine: Xie, Choi and Al-Aly, 175 outcomes in VA records (PubMed record) · Gallup: GLP-1 use reaches new high, 2026 · Novo Nordisk: Wegovy pill launch and prices, Jan 2026 · White House: most-favored-nation deals, Nov 2025 · CMS: BALANCE model · FDA: action on non-approved GLP-1 copies, Feb 2026 · FDA: compounding policy as supply stabilises · Hims & Hers: Novo agreement, filed with the SEC, Mar 2026 · Lilly: Foundayo approval and ATTAIN-1 · Lilly: retatrutide TRIUMPH-4 · Novo Nordisk: CagriSema REDEFINE 4 · Amgen: MariTide Phase 2 · Pfizer: VESPER-3 · Roche: enicepatide results · Structure Therapeutics: aleniglipron data · Dr. Reddy's: India launch, filed with the SEC · Anvisa: Ozivy registered, patent expiry, May 2026 · FDA: first generic once-daily GLP-1 (liraglutide) · FDA: Wegovy approved for heart risk · FDA: Zepbound approved for sleep apnoea · FDA: Wegovy approved for MASH · NEJM: SUMMIT trial in heart failure (PubMed record) · JAMA Psychiatry: semaglutide and alcohol (Hendershot et al.) · IARC: body fatness and cancer (13 cancers) · EMA: NAION a very rare side effect of semaglutide · JAMA: STEP-4 (PubMed record) · JAMA: SURMOUNT-4 (PubMed record) · USDA ERS: food service market segments · Snack Food & Wholesale Bakery: salty snack sales (Circana data), Mar 2026 · Reuters (via WSAU): Conagra forecast and dividend, Jul 2026 · Reuters (via Investing.com): General Mills cuts forecast, Feb 2026 · Reuters (via Euronext): PepsiCo cuts forecast, Oct 2026 · AP: PepsiCo outlook, tariffs, Apr 2025 · AP: Smucker buys Hostess, Sep 2023 · Reuters (via Investing.com): Smucker forecast, Jun 2025 · AP: Constellation and Hispanic beer buyers, Sep 2025 · Reuters (via Investing.com): Diageo warns on Latin America, Nov 2023 · Reuters (via Investing.com): Planet Fitness CEO exit, Sep 2023 · Reuters (via MarketScreener): Abbott infant-formula verdict, Jul 2024 · Abbott: full-year 2025 results · Reuters (via WDEZ): Insulet cuts forecast, Aug 2026 · Reuters (via Investing.com): Dexcom cuts forecast, Jul 2024 · Medtronic: fiscal 2026 results · United Airlines: Q3 2026 results · Costco: fiscal 2026 Form 10-K · Intuitive Surgical: Q3 2026 results, filed with the SEC · Viking Therapeutics: VK2809 liver-disease data, Jun 2024 · Lilly: Q4 2025 results, filed with the SEC · ResMed: fiscal 2026 Form 10-K · KFF: Health Tracking Poll, March 2026 topline · KFF: Health Tracking Poll, May 2024 · Census Bureau: 2025 American Community Survey households (via its October 2026 story) · Mass General Brigham Health Plan: MassHealth GLP-1 coverage notice · Rhode Island EOHHS: pharmacy notice · TennCare: provider notice on obesity drugs (via OptumRx) · Lilly: retatrutide filing plans, Jul 2026 · Novo Nordisk: legal action against Hims, Feb 2026 · FDA: Ozempic label (FLOW, section 14) · NEJM: STEP-1 (PubMed record) · NEJM: SURMOUNT-1 (PubMed record) · NEJM: STEP 9, knee arthritis (PubMed record) · NEJM: STEP-HFpEF (PubMed record) · The Lancet: Klausen et al., semaglutide and alcohol (PubMed record) · Zepbound: prescribing information · Wegovy: prescribing information · Reuters (via KFGO): Viking's weight-loss drug trial, Feb 2024 · Circana: Chain Reactions, GLP-1 use and non-food categories · Kroger: $7.5 billion share repurchase, Dec 2024 · FDA: Mounjaro drug trial snapshot · FDA: Wegovy approved for weight management, June 2021 (copy on BioSpace) · WeightWatchers: Q2 2025 Form 10-Q (bankruptcy) · Numerator: protein market trends · Viking Therapeutics: 2025 Form 10-K (VENTURE-Oral)

Accessed Nov 4, 2026: Bridge Michigan: Blue Cross Blue Shield of Michigan won't cover weight-loss drugs, Jun 2024 · Bloomberg (via Fortune): selloff in candy and beer stocks, Oct 2023 · Reuters (via Yahoo Finance): ResMed shares and GLP-1 questions, Oct 2023 · Journal of Marketing Research: Hristakeva, Liaukonytė and Feler · Roche: enicepatide Phase III studies, Sep 2026 · Viking Therapeutics: VENTURE results, SEC filing, Feb 2024 · ResMed: fiscal 2023 results, SEC filing · Walmart: Q2 FY2027 results, Aug 2026 · Meridian: Michigan Medicaid GLP-1 coverage bulletin · DHCS: Medi-Cal Rx GLP-1 member notice · NH Healthy Families: GLP-1 coverage change · Pennsylvania DHS: GLP-1 bulletin · SC Daily Gazette: South Carolina Medicaid and weight-loss drugs, Nov 2025 · WashU Medicine: Al-Aly's 175-outcomes study · Economics Observatory: the Cornell authors on the weekly shop · Journal of Marketing Research: supplement (data period) · North Carolina State Health Plan: statement on GLP-1 coverage, Mar 2024 (read via the Internet Archive) · CMS: status update on the Bridge, BALANCE and Part D, Apr 2026 · NBER: Diamond, working paper 35387, June 2026

Accessed Nov 9, 2026: FDA: Drug Safety Communication, safety labeling changes for GLP-1 receptor agonists (NAION), Nov 9, 2026 · FDA MedWatch bulletin: GLP-1 receptor agonists and NAION, Nov 9, 2026 · NBC News (Berkeley Lovelace Jr.): FDA orders new warning on GLP-1s over rare eye condition linked to sudden blindness, Nov 9, 2026 · BioSpace: FDA orders class-wide GLP-1 label update for rare eye disease, Nov 9, 2026

Quoting this? You may quote short excerpts under our reuse policy. Please credit WhyMyStockMoved.com and link to this page.

Disclosure: one or more of our editors own shares of companies named in this article (HIMS, VKTX) as a long-term investment. For education only, not investment advice. Full disclaimer.

Spot an error or have a question? · Corrections policy